SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

Rhea-AI Summary

SCYNEXIS (NASDAQ: SCYX), a biotechnology company focused on developing innovative medicines for difficult-to-treat and drug-resistant infections, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. David Angulo, M.D., President and CEO of SCYNEXIS, will engage in a fireside chat on Thursday, October 17, at 11:30 A.M. ET.

The event will be held virtually, and interested parties can sign up to view the presentation through a provided link. Additionally, one-on-one investor meetings will be available after the event upon request, which can be arranged through a separate link or by contacting a Maxim representative.

JERSEY CITY, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, at 11:30 A.M. ET.

Maxim Healthcare Virtual Summit Details:
Format:	Fireside chat
Date:	Thursday, October 17, 2024
Time:	11:30 A.M. ET
Location:	Virtual

To sign up to view the presentation, click here.

1x1 investor meetings will be available after the event upon request through the following link or by contacting your Maxim representative.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps”. Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) approved BREXAFEMME^® (ibrexafungerp tablets) in June 2021, for its first indication in vulvovaginal candidiasis (VVC), followed by a second indication in November 2022, for reduction in the incidence of recurrent VVC. Late-stage clinical investigation of ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. Additional antifungal assets from this novel class are currently in pre-clinical and discovery phase, including the compound SCY-247. For more information, visit www.scynexis.com.

CONTACT: 
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com

FAQ

When is SCYNEXIS (SCYX) participating in the 2024 Maxim Healthcare Virtual Summit?

SCYNEXIS (SCYX) is participating in the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024, at 11:30 A.M. ET.

Who will represent SCYNEXIS (SCYX) at the 2024 Maxim Healthcare Virtual Summit?

David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS, will represent the company in a fireside chat at the 2024 Maxim Healthcare Virtual Summit.

What is the format of SCYNEXIS's (SCYX) presentation at the 2024 Maxim Healthcare Virtual Summit?

SCYNEXIS's presentation at the 2024 Maxim Healthcare Virtual Summit will be in a fireside chat format.

How can investors view SCYNEXIS's (SCYX) presentation at the 2024 Maxim Healthcare Virtual Summit?

Investors can sign up to view SCYNEXIS's presentation at the 2024 Maxim Healthcare Virtual Summit through a link provided in the press release.

Are one-on-one meetings available with SCYNEXIS (SCYX) management after the 2024 Maxim Healthcare Virtual Summit?

Yes, one-on-one investor meetings with SCYNEXIS management will be available after the event upon request, which can be arranged through a provided link or by contacting a Maxim representative.